183 related articles for article (PubMed ID: 16643206)
1. Hepatotoxicity of antiretroviral drugs in HIV HCV patients with congenital coagulopathies followed at an Haemophilia Unit during a decade.
Sauleda S; Martorell M; Esteban JI; Tural C; Ruiz I; Puig L; Esteban R; Guardia J; Vargas V
Haemophilia; 2006 May; 12(3):228-36. PubMed ID: 16643206
[TBL] [Abstract][Full Text] [Related]
2. Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection.
Aranzabal L; Casado JL; Moya J; Quereda C; Diz S; Moreno A; Moreno L; Antela A; Perez-Elias MJ; Dronda F; Marín A; Hernandez-Ranz F; Moreno A; Moreno S
Clin Infect Dis; 2005 Feb; 40(4):588-93. PubMed ID: 15712082
[TBL] [Abstract][Full Text] [Related]
3. Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in HIV-HCV co-infected patients: results from the Italian EPOKA-MASTER Cohort.
Torti C; Lapadula G; Casari S; Puoti M; Nelson M; Quiros-Roldan E; Bella D; Pastore G; Ladisa N; Minoli L; Sotgiu G; Mazzotta F; Lo Caputo S; Di Perri G; Filice G; Tinelli C; Carosi G;
BMC Infect Dis; 2005 Jul; 5():58. PubMed ID: 16018804
[TBL] [Abstract][Full Text] [Related]
4. Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996-2001.
Law WP; Dore GJ; Duncombe CJ; Mahanontharit A; Boyd MA; Ruxrungtham K; Lange JM; Phanuphak P; Cooper DA
AIDS; 2003 Oct; 17(15):2191-9. PubMed ID: 14523276
[TBL] [Abstract][Full Text] [Related]
5. HAART and liver: is it safe?
Antonello VS; Kliemann DA; Rigel Santos B; Tovo CV
J Infect Dev Ctries; 2014 Nov; 8(11):1444-50. PubMed ID: 25390056
[TBL] [Abstract][Full Text] [Related]
6. Antiretroviral therapy-related hepatotoxicity: predictors and clinical management.
Dore G
J HIV Ther; 2003 Nov; 8(4):96-100. PubMed ID: 14671507
[TBL] [Abstract][Full Text] [Related]
7. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections.
Sulkowski MS; Thomas DL; Mehta SH; Chaisson RE; Moore RD
Hepatology; 2002 Jan; 35(1):182-9. PubMed ID: 11786975
[TBL] [Abstract][Full Text] [Related]
8. Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-infected patients.
Labarga P; Soriano V; Vispo ME; Pinilla J; Martin-Carbonero L; Castellares C; Casado R; Maida I; Garcia-Gasco P; Barreiro P
J Infect Dis; 2007 Sep; 196(5):670-6. PubMed ID: 17674307
[TBL] [Abstract][Full Text] [Related]
9. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection.
Qurishi N; Kreuzberg C; Lüchters G; Effenberger W; Kupfer B; Sauerbruch T; Rockstroh JK; Spengler U
Lancet; 2003 Nov; 362(9397):1708-13. PubMed ID: 14643119
[TBL] [Abstract][Full Text] [Related]
10. Period of onset and lack of clinical manifestation of hepatotoxicity after commencing highly active antiretroviral therapy.
Ugiagbe RA; Ugiagbe EE
Niger J Clin Pract; 2012; 15(1):63-7. PubMed ID: 22437093
[TBL] [Abstract][Full Text] [Related]
11. Acute liver enzyme elevations in HIV-1-infected patients.
Livry C; Binquet C; Sgro C; Froidure M; Duong M; Buisson M; Grappin M; Quantin C; Portier H; Chavanet P; Piroth L
HIV Clin Trials; 2003; 4(6):400-10. PubMed ID: 14628283
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection.
den Brinker M; Wit FW; Wertheim-van Dillen PM; Jurriaans S; Weel J; van Leeuwen R; Pakker NG; Reiss P; Danner SA; Weverling GJ; Lange JM
AIDS; 2000 Dec; 14(18):2895-902. PubMed ID: 11153671
[TBL] [Abstract][Full Text] [Related]
13. The prevalence and risk of hepatitis flares in a Serbian cohort of HIV and HCV co-infected patients treated with HAART.
Jevtović Dj; Ranin J; Salemović D; Pesić I; Dragović G; Zerjav S; Djurković-Djaković O
Biomed Pharmacother; 2008 Jan; 62(1):21-5. PubMed ID: 17223307
[TBL] [Abstract][Full Text] [Related]
14. Hepatotoxicity from first line antiretroviral therapy: an experience from a resource limited setting.
Kalyesubula R; Kagimu M; Opio KC; Kiguba R; Semitala CF; Schlech WF; Katabira ET
Afr Health Sci; 2011 Mar; 11(1):16-23. PubMed ID: 21572852
[TBL] [Abstract][Full Text] [Related]
15. Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy.
Wit FW; Weverling GJ; Weel J; Jurriaans S; Lange JM
J Infect Dis; 2002 Jul; 186(1):23-31. PubMed ID: 12089658
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of conditions associated with human immunodeficiency and hepatitis virus infections among persons with haemophilia, 2001-2003.
Goedert JJ;
Haemophilia; 2005 Sep; 11(5):516-28. PubMed ID: 16128897
[TBL] [Abstract][Full Text] [Related]
17. [Rate and risk factors of liver toxicity in patients receiving antiretroviral therapy].
Lana R; Núñez M; Mendoza JL; Soriano V
Med Clin (Barc); 2001 Nov; 117(16):607-10. PubMed ID: 11714465
[TBL] [Abstract][Full Text] [Related]
18. Prospective, open-label comparative study of liver toxicity in an unselected population of HIV-infected patients treated for the first time with efavirenz or nevirapine.
Manfredi R; Calza L; Chiodo F
HIV Clin Trials; 2005; 6(6):302-11. PubMed ID: 16452064
[TBL] [Abstract][Full Text] [Related]
19. Longitudinal effect of antiretroviral therapy on markers of hepatic toxicity: impact of hepatitis C coinfection.
French AL; Benning L; Anastos K; Augenbraun M; Nowicki M; Sathasivam K; Terrault NA
Clin Infect Dis; 2004 Aug; 39(3):402-10. PubMed ID: 15307009
[TBL] [Abstract][Full Text] [Related]
20. Liver injury in HIV-1-infected patients receiving non-nucleosides reverse transcriptase inhibitors-based antiretroviral therapy.
Li ZC; Li HJ; Dai LL; Gao YQ; Cai WP; Li HY; Huang XJ; Zhang T; Wu H
Chin Med J (Engl); 2010 Dec; 123(24):3587-90. PubMed ID: 22166636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
